Herzinsuffizienz und Diabetes – therapeutische Möglichkeiten

Abstract

Chronic heart failure is a common syndrome in industrial nations. Many of these patients also suffer from type 2 diabetes mellitus. The effects of mortality-reducing therapeutically approaches in patients with heart failure and reduced left ventricular function are independently of diabetes. By the authorization of new substances, the treatment of type 2 diabetes mellitus has made considerable progress in the recent years and changed treatment strategies. This also affects the treatment of diabetic patients with heart failure. Not only the change of paradigm in the use of metformin, but also new favorable outcome data for substances like GLP1-analoga and SGLT2-antagonists, will likely change therapeutic strategies for patients with heart failure in future.

• Literatur

• 1 Ponikowski P, Voors AA, Anker SD et al. Authors/Task FM, Document R 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;
• 2 Rydén L, Grant PJ, Anker SD. ESC Committee for Practice Guidelines. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087
• 3 McMurray JJ, Packer M, Desai AS et al. PARADIGM-HF IAC. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
• 4 Kristensen SL, Preiss D, Jhund PS et al. PARADIGM-HF IAC. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9
• 5 Standl E, Schnell O, McGuire DK. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circ Res 2016; 118: 1830-1843
• 6 Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257
• 7 Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;
• 8 Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2016; 374: 1094